694:HKEXBeijing Capital International Airport Co., Ltd. Class H Analysis
Data as of 2026-06-09 - not real-time
MYR 2.74
Latest Price
6/10Risk
Risk Level: Medium
Executive Summary
Celcomdigi Berhad is trading at its 52‑week low of 2.74 MYR, hugging a key support level and showing an RSI of 25, which points to oversold conditions. The MACD is in a bearish configuration and the stock’s beta of 0.36 signals low relative volatility, though the 30‑day price volatility hovers near 29%. On the fundamentals side, the company appears overvalued, with a DCF‑derived fair value of roughly 1.25 MYR versus the current price, and a PE of 21 versus an industry average of 17. The dividend yield is attractive at 4.9%, but a payout ratio exceeding 110% raises questions about sustainability. Additionally, the balance sheet is heavily leveraged, reflected in a debt‑to‑equity ratio of over 90, while revenue growth is essentially flat.
Given these mixed signals, the short‑term outlook is tempered by technical oversoldness and a potential bounce off support, whereas medium‑ and long‑term prospects are clouded by valuation gaps, high leverage, and dividend sustainability concerns.
Given these mixed signals, the short‑term outlook is tempered by technical oversoldness and a potential bounce off support, whereas medium‑ and long‑term prospects are clouded by valuation gaps, high leverage, and dividend sustainability concerns.
Market Outlook
Short Term
< 1 yearPositive
Model confidence: 6/10
Key Factors
- Oversold RSI indicating potential price rebound
- Price at strong support level
- Low beta suggesting limited downside volatility
Medium Term
1–3 yearsNeutral
Model confidence: 5/10
Key Factors
- Overvaluation relative to DCF fair value
- High debt‑to‑equity ratio stressing balance sheet
- Dividend payout exceeding earnings
Long Term
> 3 yearsCautious
Model confidence: 7/10
Key Factors
- Significant valuation gap with fair value
- Sustained high leverage and weak revenue growth
- Unsustainable dividend policy
Key Metrics & Analysis
Financial Health
Revenue Growth-0.20%
Profit Margin11.88%
P/E Ratio21.1
ROE9.74%
ROA6.77%
Debt/Equity91.49
P/B Ratio2.0
Op. Cash FlowMYR4.0B
Free Cash FlowMYR2.2B
Industry P/E17.0
Technical Analysis
TrendNeutral
RSI25.3
SupportMYR 2.74
ResistanceMYR 3.22
MA 20MYR 3.02
MA 50MYR 3.01
MA 200MYR 3.33
MACDBearish
VolumeIncreasing
Fear & Greed Index85.36
Valuation
Fair ValueMYR 1.25
Target PriceMYR 3.59
Upside/Downside30.87%
GradeOvervalued
TypeValue
Dividend Yield4.89%
Risk Assessment
Beta0.37
Volatility28.94%
Sector RiskMedium
Reg. RiskMedium
Geo RiskMedium
Currency RiskMedium
Liquidity RiskMedium
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.